Director Share Purchase

Accrol group

23/07/2021 14:35

RNS Number : 3381G

Accrol Group Holdings PLC

23 July 2021

 

 

23 July 2021

 

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.

 

Accrol Group Holdings plc

("Accrol" or the "Company")

 

Director Share Purchase

 

Accrol (AIM:ACRL), the UK's leading independent tissue convertor, announces that Dan Wright, Executive Chairman of Accrol, has today purchased 232,558 ordinary shares of £0.001 each ("Ordinary Shares") at a price of £0.43 per Ordinary Share.

Following this purchase, he now holds 11,515,5431 Ordinary Shares representing 3.61% of the current Issued Share Capital of the Company.

1
8,476,713 of these shares are registered in the name of Gomrath Limited, a family investment company controlled by Dan Wright

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 


 1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Dan Wright
2
Reason for the notification
a)
Position/status
Executive Chairman
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Accrol Group Holdings plc
b)
LEI
213800MC56M5G69RJ226
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Identification code
Ordinary shares of £0.001 each
ISIN: GB00BZ6VT592
b)
Nature of the transaction
Purchase of Ordinary Shares
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£0.43
232,558
d)
Aggregated information
- Aggregated volume
- Price
N/A - Single transaction
e)
Date of the transaction
23 July 2021
f)
Place of the transaction
London Stock Exchange, AIM

 

 

For further information, please contact:
Accrol Group Holdings plc
Dan Wright, Executive Chairman
Via Belvedere Communications
Gareth Jenkins, Chief Executive Officer
Richard Newman, Chief Financial Officer
Zeus Capital Limited(Nominated Adviser & Broker)
Dan Bate / Jordan Warburton
Tel: +44 (0) 161 831 1512
Dominic King / John Goold
Tel: +44 (0) 203 829 5000
Liberum Capital Limited (Joint Broker)
Tel: +44 (0) 20 3100 2222
Clayton Bush / Edward Thomas
Belvedere Communications Limited
Cat Valentine
Tel: +44 (0) 7715 769 078
Keeley Clarke
Tel: +44 (0) 7967 816 525
Llew Angus
Tel: +44 (0) 7407 023 147
accrolpr@belvederepr.com

 

Overview of Accrol

 

Accrol Group Holdings plc is a leading tissue converter and supplier of toilet tissues, kitchen rolls, facial tissues, and wet wipes to many of the UK's leading discounters and grocery retailers across the UK. Following the recent acquisitions of LTC in Leicester and JD in Flint, North Wales, the Group now operates from six manufacturing sites, including four in Lancashire, which generate revenues totalling c.16% of the £2.1bn UK retail tissue market.

 

For more information, please visit www.accrol.co.uk

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
DSHUOOORAAUBUAR